Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 5.34 Million JPY | -77.97% |
| 2022 | 24.24 Million JPY | 108.04% |
| 2021 | 11.65 Million JPY | 11.31% |
| 2020 | 10.47 Million JPY | -29.8% |
| 2019 | 14.91 Million JPY | 34.85% |
| 2018 | 11.06 Million JPY | -40.46% |
| 2017 | 18.58 Million JPY | 22.9% |
| 2016 | 15.11 Million JPY | -3.77% |
| 2015 | 15.71 Million JPY | -16.35% |
| 2014 | 18.78 Million JPY | -13.1% |
| 2013 | 21.61 Million JPY | 19.73% |
| 2012 | 18.05 Million JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 4.27 Million JPY | -17.6% |
| 2024 Q1 | 5.19 Million JPY | -2.81% |
| 2023 Q2 | 8.95 Million JPY | -0.8% |
| 2023 Q1 | 9.02 Million JPY | -62.79% |
| 2023 Q4 | 5.34 Million JPY | -51.25% |
| 2023 Q3 | 10.95 Million JPY | 22.42% |
| 2023 FY | 5.34 Million JPY | -77.97% |
| 2022 Q4 | 24.24 Million JPY | 115.26% |
| 2022 FY | 24.24 Million JPY | 108.04% |
| 2022 Q1 | 11.52 Million JPY | -1.11% |
| 2022 Q2 | 11.4 Million JPY | -1.07% |
| 2022 Q3 | 11.26 Million JPY | -1.22% |
| 2021 Q2 | 10.98 Million JPY | -14.19% |
| 2021 Q3 | 10.02 Million JPY | -8.7% |
| 2021 Q4 | 11.65 Million JPY | 16.27% |
| 2021 FY | 11.65 Million JPY | 11.31% |
| 2021 Q1 | 12.79 Million JPY | 22.18% |
| 2020 Q1 | 10.03 Million JPY | -32.7% |
| 2020 FY | 10.47 Million JPY | -29.8% |
| 2020 Q2 | 10.09 Million JPY | 0.51% |
| 2020 Q3 | 10.35 Million JPY | 2.63% |
| 2020 Q4 | 10.47 Million JPY | 1.13% |
| 2019 Q1 | 10.95 Million JPY | -0.99% |
| 2019 Q4 | 14.91 Million JPY | 27.34% |
| 2019 Q3 | 11.71 Million JPY | 11.49% |
| 2019 FY | 14.91 Million JPY | 34.85% |
| 2019 Q2 | 10.5 Million JPY | -4.06% |
| 2018 Q3 | 16.99 Million JPY | 1.6% |
| 2018 Q4 | 11.06 Million JPY | -34.89% |
| 2018 FY | 11.06 Million JPY | -40.46% |
| 2018 Q2 | 16.72 Million JPY | -8.51% |
| 2018 Q1 | 18.28 Million JPY | -1.61% |
| 2017 Q2 | 12.49 Million JPY | -11.43% |
| 2017 FY | 18.58 Million JPY | 22.9% |
| 2017 Q4 | 18.58 Million JPY | 33.87% |
| 2017 Q3 | 13.87 Million JPY | 11.04% |
| 2017 Q1 | 14.11 Million JPY | -6.65% |
| 2016 Q4 | 15.11 Million JPY | -0.1% |
| 2016 Q3 | 15.13 Million JPY | 1.56% |
| 2016 Q2 | 14.9 Million JPY | -5.9% |
| 2016 Q1 | 15.83 Million JPY | 0.8% |
| 2016 FY | 15.11 Million JPY | -3.77% |
| 2015 Q4 | 15.71 Million JPY | -4.5% |
| 2015 Q2 | 16.39 Million JPY | -10.99% |
| 2015 FY | 15.71 Million JPY | -16.35% |
| 2015 Q3 | 16.45 Million JPY | 0.34% |
| 2015 Q1 | 18.42 Million JPY | -1.91% |
| 2014 FY | 18.78 Million JPY | -13.1% |
| 2014 Q2 | 22.91 Million JPY | 5.87% |
| 2014 Q1 | 21.64 Million JPY | 0.15% |
| 2014 Q4 | 18.78 Million JPY | -21.55% |
| 2014 Q3 | 23.94 Million JPY | 4.47% |
| 2013 FY | 21.61 Million JPY | 19.73% |
| 2013 Q4 | 21.61 Million JPY | 0.0% |
| 2012 FY | 18.05 Million JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | 99.218% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | 70.205% |
| GNI Group Ltd. | 2.33 Billion JPY | 99.771% |
| Linical Co., Ltd. | - JPY | -Infinity% |
| Trans Genic Inc. | 2.22 Billion JPY | 99.76% |
| MEDINET Co., Ltd. | 67.48 Million JPY | 92.084% |
| Soiken Holdings Inc. | 1.12 Billion JPY | 99.523% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | 94.84% |
| AnGes, Inc. | 1.61 Billion JPY | 99.669% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | 92.781% |
| Nxera Pharma Co., Ltd. | 2.9 Billion JPY | 99.816% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | 98.341% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | -2803.261% |
| Carna Biosciences, Inc. | 140.14 Million JPY | 96.188% |
| CanBas Co., Ltd. | 728 Thousand JPY | -633.791% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | 93.92% |
| RaQualia Pharma Inc. | 147.93 Million JPY | 96.389% |
| Chiome Bioscience Inc. | 64.1 Million JPY | 91.667% |
| Kidswell Bio Corporation | 875.65 Million JPY | 99.39% |
| PeptiDream Inc. | 2.4 Billion JPY | 99.778% |
| Ribomic Inc. | 2.27 Million JPY | -134.916% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | - JPY | -Infinity% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | -534199900.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | 85.161% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | 29 Million JPY | 81.579% |
| CellSource Co., Ltd. | 305.92 Million JPY | 98.254% |
| FunPep Company Limited | 25.54 Million JPY | 79.085% |
| Kringle Pharma, Inc. | 364.05 Million JPY | 98.533% |
| Stella Pharma Corporation | 1.11 Billion JPY | 99.521% |
| TMS Co., Ltd. | 50.02 Million JPY | 89.321% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | 74.441% |
| Cuorips Inc. | 1.04 Million JPY | -412.176% |
| K Pharma,Inc. | 10.79 Million JPY | 50.51% |
| Takara Bio Inc. | 11.85 Billion JPY | 99.955% |
| ReproCELL Incorporated | 248.14 Million JPY | 97.847% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | 98.814% |
| StemCell Institute Inc. | 42.26 Million JPY | 87.36% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | 97.663% |
| CellSeed Inc. | 46.19 Million JPY | 88.435% |